Reply
Mussarat N. Rahim, Michael A. Heneghan – 25 July 2019
Mussarat N. Rahim, Michael A. Heneghan – 25 July 2019
Amar Gupta, Sumeet K. Asrani – 25 July 2019
Konstantina Kyritsi, Lixian Chen, April O’Brien, Heather Francis, Travis W. Hein, Julie Venter, Nan Wu, Ludovica Ceci, Tianhao Zhou, David Zawieja, Anatoliy A. Gashev, Fanyin Meng, Pietro Invernizzi, Luca Fabris, Chaodong Wu, Nicholas J. Skill, Romil Saxena, Suthat Liangpunsakul, Gianfranco Alpini, Shannon S. Glaser – 25 July 2019
Xiu‐Ping Zhang, Yu‐Zhen Gao, Zhen‐Hua Chen, Shu‐Qun Cheng – 25 July 2019
Ioannis A. Ziogas, Dirk J. Windt, Gregory C. Wilson, Alessandro Furlan, Michael A. Nalesnik, Samer Tohme, David A. Geller – 25 July 2019
Manhal Izzy, Lisa B. VanWagner, Grace Lin, Mario Altieri, James Y. Findlay, Jae K. Oh, Kymberly D. Watt, Samuel S. Lee, on behalf of The Cirrhotic Cardiomyopathy Consortium – 25 July 2019 – Cirrhotic cardiomyopathy (CCM) is cardiac dysfunction in patients with end‐stage liver disease in the absence of prior heart disease. First defined in 2005 during the World Congress of Gastroenterology, CCM criteria consisted of echocardiographic parameters to identify subclinical cardiac dysfunction in the absence of overt structural abnormalities.
Florence Wong, K. Rajender Reddy, Jacqueline G. O’Leary, Guadalupe Garcia‐Tsao, Patrick S. Kamath, Jasmohan S. Bajaj, for the North American Consortium for the Study of the Liver – 25 July 2019
Lingdi Wang, Lu Zhu, Kaiyuan Wu, Yong Chen, Duck‐Yeon Lee, Marjan Gucek, Michael N. Sack – 25 July 2019
Neil Mehta, Jennifer L. Dodge, Joshua D. Grab, Francis Y. Yao – 25 July 2019
Claire L. Jansson‐Knodell, Samer Gawrieh, Adam D. McIntyre, Tiebing Liang, Robert A. Hegele, Naga Chalasani – 25 July 2019